These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 33717084)

  • 1. The Roles of Sclerostin in Immune System and the Applications of Aptamers in Immune-Related Research.
    Sun M; Chen Z; Wu X; Yu Y; Wang L; Lu A; Zhang G; Li F
    Front Immunol; 2021; 12():602330. PubMed ID: 33717084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection and Characterization of Single-Stranded DNA Aptamers Binding Human B-Cell Surface Protein CD20 by Cell-SELEX.
    Haghighi M; Khanahmad H; Palizban A
    Molecules; 2018 Mar; 23(4):. PubMed ID: 29561802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wnt Antagonists in Hematopoietic and Immune Cell Fate: Implications for Osteoporosis Therapies.
    Chicana B; Donham C; Millan AJ; Manilay JO
    Curr Osteoporos Rep; 2019 Apr; 17(2):49-58. PubMed ID: 30835038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sclerostin inhibits interleukin-1β-induced late stage chondrogenic differentiation through downregulation of Wnt/β-catenin signaling pathway.
    Miyatake K; Kumagai K; Imai S; Yamaguchi Y; Inaba Y
    PLoS One; 2020; 15(9):e0239651. PubMed ID: 32976505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel actions of sclerostin on bone.
    Holdsworth G; Roberts SJ; Ke HZ
    J Mol Endocrinol; 2019 Feb; 62(2):R167-R185. PubMed ID: 30532996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wnt Signaling in the Regulation of Immune Cell and Cancer Therapeutics.
    Haseeb M; Pirzada RH; Ain QU; Choi S
    Cells; 2019 Nov; 8(11):. PubMed ID: 31684152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sclerostin: from bench to bedside.
    Tanaka S; Matsumoto T
    J Bone Miner Metab; 2021 May; 39(3):332-340. PubMed ID: 33206222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sclerostin and Vascular Pathophysiology.
    Catalano A; Bellone F; Morabito N; Corica F
    Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32640551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SELEX methods on the road to protein targeting with nucleic acid aptamers.
    Bayat P; Nosrati R; Alibolandi M; Rafatpanah H; Abnous K; Khedri M; Ramezani M
    Biochimie; 2018 Nov; 154():132-155. PubMed ID: 30193856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aptamers: new arrows to target dendritic cells.
    Ganji A; Varasteh A; Sankian M
    J Drug Target; 2016; 24(1):1-12. PubMed ID: 25950603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptor protein STAP-2 modulates cellular signaling in immune systems.
    Sekine Y
    Biol Pharm Bull; 2014; 37(2):185-94. PubMed ID: 24492713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aptamer modules as sensors and detectors.
    Famulok M; Mayer G
    Acc Chem Res; 2011 Dec; 44(12):1349-58. PubMed ID: 21819040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. microRNA-96 promotes osteoblast differentiation and bone formation in ankylosing spondylitis mice through activating the Wnt signaling pathway by binding to SOST.
    Ma S; Wang DD; Ma CY; Zhang YD
    J Cell Biochem; 2019 Sep; 120(9):15429-15442. PubMed ID: 31111563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unraveling Prion Protein Interactions with Aptamers and Other PrP-Binding Nucleic Acids.
    Macedo B; Cordeiro Y
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28513534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a DNA aptamer that inhibits sclerostin's antagonistic effect on Wnt signalling.
    Shum KT; Chan C; Leung CM; Tanner JA
    Biochem J; 2011 Mar; 434(3):493-501. PubMed ID: 21204783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel insights into the role of aptamers in the fight against cancer.
    Maimaitiyiming Y; Hong F; Yang C; Naranmandura H
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):797-810. PubMed ID: 30830295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three decades of nucleic acid aptamer technologies: Lessons learned, progress and opportunities on aptamer development.
    Wang T; Chen C; Larcher LM; Barrero RA; Veedu RN
    Biotechnol Adv; 2019; 37(1):28-50. PubMed ID: 30408510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dimerization of an aptamer generated from Ligand-guided selection (LIGS) yields a high affinity scaffold against B-cells.
    Batool S; Argyropoulos KV; Azad R; Okeoma P; Zumrut H; Bhandari S; Dekhang R; Mallikaratchy PR
    Biochim Biophys Acta Gen Subj; 2019 Jan; 1863(1):232-240. PubMed ID: 30342154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aptamer applications for targeted cancer therapy.
    Barbas AS; Mi J; Clary BM; White RR
    Future Oncol; 2010 Jul; 6(7):1117-26. PubMed ID: 20624124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aptamers: A Feasible Technology in Cancer Immunotherapy.
    Soldevilla MM; Villanueva H; Pastor F
    J Immunol Res; 2016; 2016():1083738. PubMed ID: 27413756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.